Acquired resistance to targeted therapies against oncogene-driven non-small-cell lung cancer: approach to subtyping progressive disease and clinical implications.

[1]  A. Shaw,et al.  Novel targets in non-small cell lung cancer: ROS1 and RET fusions. , 2013, The oncologist.

[2]  Li Zhang,et al.  Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial. , 2013, The Lancet. Oncology.

[3]  Michael Thomas,et al.  Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. , 2013, The New England journal of medicine.

[4]  J. Engelman,et al.  ALK in lung cancer: past, present, and future. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  Tianhong Li,et al.  Genotyping and genomic profiling of non-small-cell lung cancer: implications for current and future therapies. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  D. Camidge,et al.  Response to crizotinib rechallenge after initial progression and intervening chemotherapy in ALK lung cancer. , 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[7]  R. Rosell,et al.  Adaptive resistance to targeted therapies in cancer. , 2013, Translational lung cancer research.

[8]  P. Bunn,et al.  Local Ablative Therapy of Oligoprogressive Disease Prolongs Disease Control by Tyrosine Kinase Inhibitors in Oncogene-Addicted Non–Small-Cell Lung Cancer , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[9]  Steven J. M. Jones,et al.  Comprehensive genomic characterization of squamous cell lung cancers , 2012, Nature.

[10]  Angela N. Brooks,et al.  Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing , 2012, Cell.

[11]  L. Beckett,et al.  Algorithm for codevelopment of new drug-predictive biomarker combinations: accounting for inter- and intrapatient tumor heterogeneity. , 2012, Clinical lung cancer.

[12]  Joe Y. Chang,et al.  Oligometastatic Disease at Presentation or Recurrence for Nonsmall Cell Lung Cancer , 2012, Pulmonary medicine.

[13]  L. Sequist,et al.  LUX-Lung 3: A randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  L. Beckett,et al.  Thymidylate synthase (TS) gene expression in patients with ALK positive (+) non-small cell lung cancer (NSCLC): Implications for therapy. , 2012 .

[15]  R. Doebele,et al.  Treating ALK-positive lung cancer—early successes and future challenges , 2012, Nature Reviews Clinical Oncology.

[16]  E. Felip,et al.  Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. , 2012, The Lancet. Oncology.

[17]  W. Franklin,et al.  Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non–Small Cell Lung Cancer , 2012, Clinical Cancer Research.

[18]  Yukiko Nakamura,et al.  Continuous EGFR-TKI administration following radiotherapy for non-small cell lung cancer patients with isolated CNS failure. , 2011, Lung cancer.

[19]  Lee T. Sam,et al.  Personalized Oncology Through Integrative High-Throughput Sequencing: A Pilot Study , 2011, Science Translational Medicine.

[20]  Y. Bang,et al.  Anaplastic Lymphoma Kinase Translocation: A Predictive Biomarker of Pemetrexed in Patients with Non-small Cell Lung Cancer , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[21]  S. Swindells,et al.  Prevention of HIV-1 infection with early antiretroviral therapy , 2011, Journal of Family Planning and Reproductive Health Care.

[22]  H. Groen,et al.  Activity and tolerability of afatinib (BIBW 2992) and cetuximab in NSCLC patients with acquired resistance to erlotinib or gefitinib. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  W. Franklin,et al.  Anaplastic Lymphoma Kinase Gene Rearrangements in Non-small Cell Lung Cancer are Associated with Prolonged Progression-Free Survival on Pemetrexed , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[24]  Y. Iwasa,et al.  Evolutionary Dynamics of Intratumor Heterogeneity , 2011, PloS one.

[25]  S. Antoniu.  Crizotinib for EML4-ALK positive lung adenocarcinoma: a hope for the advanced disease? , 2011, Expert opinion on therapeutic targets.

[26]  D. Gandara,et al.  Association of Epidermal Growth Factor Receptor Activating Mutations with Low ERCC1 Gene Expression in Non-small Cell Lung Cancer , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[27]  Jeffrey W. Clark,et al.  Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. , 2010, The New England journal of medicine.

[28]  A. Gemma,et al.  F1000 highlights , 2010 .

[29]  S. Toyooka,et al.  Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. , 2010, The Lancet. Oncology.

[30]  M. Kris,et al.  Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  L. Beckett,et al.  Intermittent Erlotinib in Combination with Pemetrexed: Phase I Schedules Designed to Achieve Pharmacodynamic Separation , 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[32]  J. Abbruzzese,et al.  F1000 highlights , 2009, JAMA.

[33]  R. Weichselbaum,et al.  An Initial Report of a Radiation Dose-Escalation Trial in Patients with One to Five Sites of Metastatic Disease , 2008, Clinical Cancer Research.

[34]  H. Varmus,et al.  Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain , 2005, PLoS medicine.

[35]  Daniel Jones.  Anticancer drugs: To the rescue? , 2004, Nature Reviews Drug Discovery.

[36]  D. Gandara,et al.  Intercalation of erlotinib and pemetrexed in the treatment of non-small cell lung cancer. , 2010, Current drug targets.

[37]  Lin Huan,et al.  Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer , 2010 .